amgen's xgeva delays prostate cancer bone pain
a clinical trial of amgen inc's bone drug, xgeva, found that it can significantly delay the time it takes for prostate cancer to cause bone pain -- a finding the company believes will help boost the drug's market potential.
http://feeds.reuters.com/~r/reuters/healthnews/~3/ef0_nj8-4yu/us-amgen-xgeva-idustre74g4lt20110517
11619
17 May 2011 16:43:41
reuters
health